(Registrieren)

ISS Recommends That Engelhard's Shareholders Vote 'FOR' BASF's Nominees

Geschrieben am 24-05-2006

Ludwigshafen, Germany (ots/PRNewswire) -

BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA,
SWX: AN) today announced that Institutional Shareholder Services
(ISS) has recommended that Engelhard's shareholders vote for BASF's
five nominees for election to Engelhard's Board of Directors at the
June 2 Annual Shareholders' Meeting.

ISS is a highly respected, independent proxy advisory firm, and
its voting analyses and recommendations are relied upon by hundreds
of institutional investors, mutual funds, and fiduciaries throughout
the world.

BASF is pleased that ISS has recognized the value and certainty of
BASF's all-cash offer and recommended that Engelhard's shareholders
vote "FOR" BASF's nominees.

BASF is the world's leading chemical company: The Chemical
Company. Its portfolio ranges from chemicals, plastics, performance
products, agricultural products and fine chemicals to crude oil and
natural gas. As a reliable partner to virtually all industries,
BASF's intelligent system solutions and high-value products help its
customers to be more successful. BASF develops new technologies and
uses them to open up additional market opportunities. It combines
economic success with environmental protection and social
responsibility, thus contributing to a better future. In 2005, BASF
had approximately 81,000 employees and posted sales of more than
EUR42.7 billion. BASF shares are traded on the stock exchanges in
Frankfurt (BAS), London (BFA), New York (BF) and Zurich (AN). Further
information on BASF is available on the Internet at www.basf.com.

BASF is currently soliciting proxies for use at Engelhard's 2006
annual meeting of stockholders, or at any adjournment or postponement
thereof, to vote in favor of BASF's nominees identified in the
definitive proxy statement on Schedule 14A filed with the U.S.
Securities and Exchange Commission (the "SEC") on May 12, 2006, and
to vote on any other matters that shall be voted upon at Engelhard's
2006 annual meeting of stockholders. All Engelhard stockholders are
strongly encouraged to read the definitive proxy statement, because
it contains important information. Engelhard stockholders may obtain
copies of the definitive proxy statement and related materials for
free at the SEC's website at www.sec.gov.

The identity of people who may be considered "participants in a
solicitation" of proxies from Engelhard stockholders for use at
Engelhard's 2006 annual meeting of stockholders under SEC rules and a
description of their direct and indirect interests in the
solicitation, by security holdings or otherwise, are contained in the
definitive proxy statement on Schedule 14A that BASF filed with the
SEC on May 12, 2006.

BASF may also solicit written consents of Engelhard stockholders
to (a) amend the bylaws of Engelhard to increase the number of
directors on Engelhard's Board of Directors to twelve and provide
that any newly created vacancies on Engelhard's Board of Directors
shall be filled by Engelhard's stockholders, and (b) to appoint
individuals selected by BASF to fill the vacancies created thereby
(the "Proposals"). Full details of the Proposals are contained in the
preliminary consent solicitation statement on Schedule 14A that BASF
filed with the SEC on May 15, 2006. All Engelhard stockholders are
strongly encouraged to read the preliminary consent statement and the
definitive consent statement when they are available because they
will contain important information. Engelhard stockholders may obtain
copies of the preliminary consent statement and related materials for
free at the SEC's website at www.sec.gov. The identity of people who,
under SEC rules, may be considered "participants in a solicitation"
of consents for the Proposals and a description of their direct and
indirect interests in the solicitation, by security holdings or
otherwise, are contained in the preliminary consent statement on
Schedule 14A filed with the SEC on May 15, 2006.

This press release is provided for informational purposes only and
is neither an offer to purchase nor a solicitation of an offer to
sell any securities of Engelhard Corporation. Any offers to purchase
or solicitation of offers to sell will be made only pursuant to the
tender offer statement (including the offer to purchase, the letter
of transmittal and other offer documents) which was initially filed
with the SEC on January 9, 2006. Engelhard stockholders are advised
to read these documents and any other documents relating to the
tender offer that are filed with the SEC carefully and in their
entirety because they contain important information. Engelhard
stockholders may obtain copies of these documents for free at the
SEC's website at www.sec.gov or by calling Innisfree M&A
Incorporated, the Information Agent for the offer, at +1 877 750 5837
(Toll Free from the U.S. and Canada) or 00800 7710 9971 (Toll Free
from Europe).

This press release contains forward-looking statements. All
statements contained in this press release that are not clearly
historical in nature or that necessarily depend on future events are
forward-looking, and the words "anticipate," "believe," "expect,"
"estimate," "plan," and similar expressions are generally intended to
identify forward-looking statements. These statements are based on
current expectations, estimates and projections of BASF management
and currently available information. They are not guarantees of
future performance, involve certain risks and uncertainties that are
difficult to predict and are based upon assumptions as to future
events that may not prove to be accurate.

Many factors could cause the actual results, performance or
achievements of BASF to be materially different from those that may
be expressed or implied by such statements. Such factors include
those discussed in BASF's most recent Form 20-F filed with the SEC.

Michael Grabicki
Phone: +49-621-60-99938
Fax: +49-621-60-92693
michael.grabicki@basf.com
US media contact:
Rand Pearsall
Phone: +1-973-245-6820
Fax: +1-973-245-6714
rand.pearsall@basf.com
Analysts/Investors contact:
Christoph Beumelburg
Phone: +1-973-245-6013
Cell: +1-973-519-2981
Fax: +1-973-245-6714
christoph.beumelburg@basf.com

Web site: http://www.basf.com

ots Originaltext: BASF Aktiengesellschaft
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Michael Grabicki, +49-621-60-99938, fax +49-621-60-92693,
michael.grabicki@basf.com, US - Rand Pearsall, +1-973-245-6820, fax,
+1-973-245-6714, rand.pearsall@basf.com, Investors - Christoph
Beumelburg, Phone, +1-973-245-6013, Cell, +1-973-519-2981, Fax,
+1-973-245-6714,
christoph.beumelburg@basf.com


Kontaktinformationen:

Leider liegen uns zu diesem Artikel keine separaten Kontaktinformationen gespeichert vor.
Am Ende der Pressemitteilung finden Sie meist die Kontaktdaten des Verfassers.

Neu! Bewerten Sie unsere Artikel in der rechten Navigationsleiste und finden
Sie außerdem den meist aufgerufenen Artikel in dieser Rubrik.

Sie suche nach weiteren Pressenachrichten?
Mehr zu diesem Thema finden Sie auf folgender Übersichtsseite. Desweiteren finden Sie dort auch Nachrichten aus anderen Genres.

http://www.bankkaufmann.com/topics.html

Weitere Informationen erhalten Sie per E-Mail unter der Adresse: info@bankkaufmann.com.

@-symbol Internet Media UG (haftungsbeschränkt)
Schulstr. 18
D-91245 Simmelsdorf

E-Mail: media(at)at-symbol.de

14172

weitere Artikel:
  • euro adhoc: Advanced Medien AG / Geschäftszahlen/Bilanz / Advanced Medien AG gibt vorläufige Zahlen für das Geschäftsjahr 2005 bekannt. -------------------------------------------------------------------------------- Ad hoc-Mitteilung übermittelt durch euro adhoc. Für den Inhalt ist der Emittent verantwortlich. -------------------------------------------------------------------------------- 24.05.2006 München, 24. Mai 2006 - Die Advanced Medien AG, München (ISIN DE0001262186, WKN 126218), schloss die Neuorientierung ihres Geschäftes im vergangenen Geschäftsjahr erfolgreich ab. Der Konzern erzielte in 2005 einen Umsatz in Höhe von EUR 25,9 Mio. nach EUR 14,8 Mio. im Vergleichszeitraum mehr...

  • Christal Films sichert sich Rechte zum Verleih des nächsten Woody-Allen-Films für Kanada Montreal, Kanada (ots/PRNewswire) - Es gibt auch in diesem Jahr auf dem Filmmarkt von Cannes wieder einige grosse Filmprojekte, und Christal Films Distribution ist stolz darauf, sich die Rechte für einen dieser Filme gesichert zu haben: Die Dreharbeiten zu Woody Allens nächstem Film werden im Juni in London beginnen. Christian Larouche und Sylvain Gagné (President bzw. Vice-President von Christal Films) liessen sich beide vom Charme der herrlichen Mischung aus Romanze und Hitchcock-Thriller gefangen nehmen und freuen sich darauf, die Originalität mehr...

  • Aktien mit zufallsbedingten Kursentwicklungen bei ruhigem Handel - Emerging-Market-Fonds eher nachgebend Berlin (ots) - Eigentlich konnten die Anleger mit den heutigen Vorgaben ganz zufrieden sein, Dow und Nasdaq boten Plus-Vorgaben. Es gab keine besonderen negativen Unternehmens-Nachrichten.Die Tokioter Börse schloss heute allerdings schwach, wobei rückläufige Rohstoffpreise belasteten. Die Berliner Marktteilnehmer starteten heute ganz zuversichtlich, wobei DAX und MDAX freundlicher tendierten. Viele Anleger hierzulande atmeten jetzt möglicherweise erst einmal auf. Die letzten Tage an den deutschen Börsen hatten doch für Unsicherheit gesorgt mehr...

  • Isotechnika Signs Agreement Granting Lux Biosciences Worldwide Ophthalmic Rights to ISA247 Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has signed an agreement with Lux Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences worldwide rights to develop and commercialize Isotechnika's lead drug, ISA247 for the treatment and prophylaxis of all ophthalmic diseases. ISA247 is a novel calcineurin inhibitor currently being investigated in a Phase III trial for the treatment of moderate to severe psoriasis and a Phase IIb trial for the prevention of organ rejection following mehr...

  • Osteologix, Inc. schliesst am Mittwoch, den 24. Mai 2006 Reverse Merger ab San Francisco (ots/PRNewswire) - - Sichert USD 10 Mio an Finanzierung durch Privatplatzierung Osteologix, Inc. ein Biopharmazeitischen Unternehmen mit Hauptsitz in San Francisco, Kalifornien, und Niederlassungen in Kopenhagen, Dänemark, gab heute den Abschluss eines Reverse Merger und Aktientausch-Transaktion mit dem in New York, NY, ansässigen, öffentlich gehandelten Unternehmen Castle & Morgan Holdings, Inc. (OTC) bekannt. Neben dem Zusammenschluss gab Osteologix ausserdem bekannt, dass das Unternehmen eine Finanzierung durch Privatplatzierung mehr...

Mehr zu dem Thema Finanzen

Der meistgelesene Artikel zu dem Thema:

Century Casinos wurde in Russell 2000 Index aufgenommen

durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht